NCT01678313View on ClinicalTrials.gov

Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels

PHASE2CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Benign Prostatic Hyperplasia
Interventions
DRUG

Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD)

Study group

DRUG

Doxazosin 4 mg every day (QD)

Control group

Trial Locations (1)

970

Buddhist Tzu Chi General Hospital, Hualien City

All Listed Sponsors
lead

Buddhist Tzu Chi General Hospital

OTHER

NCT01678313 - Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels | Biotech Hunter | Biotech Hunter